非小細胞肺癌(NSCLC)治療のグローバル市場予測(~2027年)

◆英語タイトル:Non-small Cell Lung Cancer Therapeutics Market Research Report by Cancer Type, Drug Class, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

360iResearchが発行した調査報告書(360iR22DC443)◆商品コード:360iR22DC443
◆発行会社(リサーチ会社):360iResearch
◆発行日:2022年10月
◆ページ数:227
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD4,949 ⇒換算¥732,452見積依頼/購入/質問フォーム
Enterprise LicenseUSD9,949 ⇒換算¥1,472,452見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

360iResearch社の本調査報告書では、2021年に144.0億ドルであった世界の非小細胞肺癌(NSCLC)治療市場規模が、2022年に154.8億ドルになり、2027年まで年平均7.66%で成長して224.3億ドルに達すると予測しています。本報告書では、非小細胞肺癌(NSCLC)治療の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、がん種類別(腺癌、大細胞癌、扁平上皮癌)分析、薬物クラス別(血管新生阻害剤、上皮細胞成長因子受容体(EGFR)阻害剤、葉酸代謝拮抗剤、キナーゼ阻害剤、微小管安定化剤)分析、販売チャネル別(病院薬局、オンライン薬局、小売薬局)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況、企業情報など、以下の項目を掲載しています。本書に記載されている企業情報としては、Astellas Pharma Inc、AstraZeneca PLC、Bristol Myers Squibb、C.H. Boehringer Sohn AG&Ko. KG、Celgene Corporation、Eisai Co., Ltd、Eli Lilly and Company、F. Hoffmann-La Roche Ltd、GlaxoSmithKline PLC、Merck KGaAなどが含まれています。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト

・世界の非小細胞肺癌(NSCLC)治療市場規模:がん種類別
- 腺癌における市場規模
- 大細胞癌における市場規模
- 扁平上皮癌における市場規模

・世界の非小細胞肺癌(NSCLC)治療市場規模:薬物クラス別
- 血管新生阻害剤の市場規模
- 上皮細胞成長因子受容体(EGFR)阻害剤の市場規模
- 葉酸代謝拮抗剤の市場規模
- キナーゼ阻害剤の市場規模
- 微小管安定化剤の市場規模

・世界の非小細胞肺癌(NSCLC)治療市場規模:販売チャネル別
- 病院薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
- 小売薬局チャネルの市場規模

・世界の非小細胞肺癌(NSCLC)治療市場規模:地域別
- 南北アメリカの非小細胞肺癌(NSCLC)治療市場規模
アメリカの非小細胞肺癌(NSCLC)治療市場規模
カナダの非小細胞肺癌(NSCLC)治療市場規模
ブラジルの非小細胞肺癌(NSCLC)治療市場規模

- アジア太平洋の非小細胞肺癌(NSCLC)治療市場規模
日本の非小細胞肺癌(NSCLC)治療市場規模
中国の非小細胞肺癌(NSCLC)治療市場規模
インドの非小細胞肺癌(NSCLC)治療市場規模
韓国の非小細胞肺癌(NSCLC)治療市場規模
台湾の非小細胞肺癌(NSCLC)治療市場規模

- ヨーロッパ/中東/アフリカの非小細胞肺癌(NSCLC)治療市場規模
イギリスの非小細胞肺癌(NSCLC)治療市場規模
ドイツの非小細胞肺癌(NSCLC)治療市場規模
フランスの非小細胞肺癌(NSCLC)治療市場規模
ロシアの非小細胞肺癌(NSCLC)治療市場規模

- その他地域の非小細胞肺癌(NSCLC)治療市場規模

・競争状況
・企業情報

The Global Non-small Cell Lung Cancer Therapeutics Market size was estimated at USD 14.40 billion in 2021 and expected to reach USD 15.48 billion in 2022, and is projected to grow at a CAGR 7.66% to reach USD 22.43 billion by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Non-small Cell Lung Cancer Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Cancer Type, the market was studied across Adenocarcinoma, Large Cell Carcinoma, and Squamous Cell Carcinoma.

Based on Drug Class, the market was studied across Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Folate Antimetabolites, Kinase Inhibitor, Microtubule Stabilizer, and PD-1/ PD-L1 Inhibitor.

Based on Distribution Channel, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Non-small Cell Lung Cancer Therapeutics market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Non-small Cell Lung Cancer Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Non-small Cell Lung Cancer Therapeutics Market, including Astellas Pharma Inc, AstraZeneca PLC, Bristol Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, Celgene Corporation, Eisai Co., Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Orion Corporation, Pfizer Inc, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Non-small Cell Lung Cancer Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Non-small Cell Lung Cancer Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Non-small Cell Lung Cancer Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Non-small Cell Lung Cancer Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Non-small Cell Lung Cancer Therapeutics Market?
6. What is the market share of the leading vendors in the Global Non-small Cell Lung Cancer Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global Non-small Cell Lung Cancer Therapeutics Market?

❖ レポートの目次 ❖

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of Non-small Cell Lung Cancer (NSCLC) across the globe due to increasing air pollution and smoking habits
5.1.1.2. Presence of a strong pipeline for NSCLC therapeutics
5.1.2. Restraints
5.1.2.1. High cost and lack of availability of the drug
5.1.3. Opportunities
5.1.3.1. Introduction of new targeted therapies and treatments
5.1.3.2. Adoption of advanced therapeutics in the developing countries
5.1.4. Challenges
5.1.4.1. Capital intensive treatment and procedures
5.2. Cumulative Impact of COVID-19

6. Non-small Cell Lung Cancer Therapeutics Market, by Cancer Type
6.1. Introduction
6.2. Adenocarcinoma
6.3. Large Cell Carcinoma
6.4. Squamous Cell Carcinoma

7. Non-small Cell Lung Cancer Therapeutics Market, by Drug Class
7.1. Introduction
7.2. Angiogenesis Inhibitor
7.3. Epidermal Growth Factor Receptor Blocker
7.4. Folate Antimetabolites
7.5. Kinase Inhibitor
7.6. Microtubule Stabilizer
7.7. PD-1/ PD-L1 Inhibitor

8. Non-small Cell Lung Cancer Therapeutics Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies

9. Americas Non-small Cell Lung Cancer Therapeutics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Astellas Pharma Inc
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. AstraZeneca PLC
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Bristol Myers Squibb
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. C.H. Boehringer Sohn AG & Ko. KG
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Celgene Corporation
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Eisai Co., Ltd
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Eli Lilly and Company
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. F. Hoffmann-La Roche Ltd
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. GlaxoSmithKline PLC
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Merck KGaA
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Novartis International AG
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Orion Corporation
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Pfizer Inc
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Sanofi S.A.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Takeda Pharmaceutical Company Limited
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 非小細胞肺癌(NSCLC)治療のグローバル市場予測(~2027年)(Non-small Cell Lung Cancer Therapeutics Market Research Report by Cancer Type, Drug Class, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆